Market
Increase in Ozempic prescriptions in Europe post-EMA label update by June 2025?
2
Novo Nordisk•Ozempic•European Medicines Agency•EMA•Harvard University•Eli Lilly•Mounjaro•Britons•Wegovy
Resolution / Starting Odds
Yes • 50%
No • 50%
Prescription data from European health agencies or pharmaceutical reports
Story
Novo Nordisk's Ozempic Label Update Approved by EMA for Risk Reduction of Kidney Disease-Related Events Amid Vision Loss Study
Dec 13, 2024, 01:46 PM
Novo Nordisk's diabetes drug Ozempic has received a positive opinion from the European Medicines Agency (EMA) to update its label, which will now reflect the drug's potential to reduce the risk of kidney disease-related events. This approval follows a study that found a small number of patients experienced vision loss linked to Ozempic, corroborating previous research from Harvard University. Concurrently, Eli Lilly's Mounjaro is gaining popularity among Britons seeking obesity treatments, surpassing Novo Nordisk's Wegovy in preference. The recent findings suggest that while Ozempic may offer significant benefits for weight management and diabetes, its association with rare vision loss raises important safety considerations for patients and healthcare providers alike.
View original story
Similar markets
Safety label update • 25%
No action taken • 25%
Other regulatory actions • 25%
Product recall • 25%
Highly positive • 25%
Neutral • 25%
Negative • 25%
Somewhat positive • 25%
No distribution approved • 25%
Approve distribution city-wide • 25%
No decision made • 25%
Approve limited distribution • 25%
Guidelines under review • 25%
No changes • 25%
Stricter guidelines issued • 25%
Guidelines relaxed • 25%
50-69% reduction • 25%
Less than 25% reduction • 25%
25-49% reduction • 25%
70% or more reduction • 25%
No campaigns • 25%
By Novo Nordisk • 25%
By health organizations • 25%
By both • 25%